# Jean-Pascal Machiels

Source: https://onco.cc/people/jean-pascal-machiels/  
OnCo record `jean-pascal-machiels` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Brussels oncologist who led KEYNOTE-412, the trial that tested adding pembrolizumab to chemoradiotherapy for locally advanced head and neck cancer.

## Summary

Jean-Pascal Machiels heads medical oncology at Cliniques universitaires Saint-Luc in Brussels and chairs the EORTC head and neck cancer group. He was first author of the 2024 Lancet Oncology report of KEYNOTE-412, the phase 3 trial of pembrolizumab with and after cisplatin-based chemoradiotherapy in locally advanced head and neck squamous-cell carcinoma, which did not reach statistical significance for event-free survival, and of the European guidelines for the disease.

## Fields

- Kind: Person
- Last checked: 2026-09-18
- Tags: head-and-neck; immunotherapy; trialist
- Role: Head of Medical Oncology, Cliniques universitaires Saint-Luc, Brussels
- Specialisms: Head and neck cancer; Chemoradiotherapy with immunotherapy; Early-phase trials

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer)](https://onco.cc/cancers/hpv-negative-head-and-neck-cancer/)
- institutions: [King Albert II Cancer Institute, Cliniques universitaires Saint-Luc](https://onco.cc/institutions/king-albert-ii-cancer-institute/)
- trials: [KEYNOTE-412](https://onco.cc/trials/keynote-412/)

---
JSON: https://onco.cc/api/v1/entities/jean-pascal-machiels.json